

### AMENDMENTS TO THE CLAIMS

1. **(Original)** A process for the expansions of TALL lymphocytes, wherein at least  $1 \times 10^9$  cells are grown in homogeneous conditions in a single fermentation unit.
2. **(Original)** The process as claimed in claim 1, wherein said fermentation unit is for anchorage dependent cells.
3. **(Original)** The process as claimed in claim 1, wherein said fermentation unit is a multi-chamber stack.
4. **(Original)** The process as claimed in claim 3, wherein said fermentation unit is a Cell-Factory™.
5. **(Original)** The process as claimed in claim 3, wherein the expansion in the homogeneous system is preceded by a process of pre – expansion in flask until obtaining a number of cells from  $0.7$  to  $1 \times 10^8$ .
6. **(Original)** The process as claimed in claim 5, wherein the cellular density of the inoculum is at least  $0.7 \times 10^6$  cells/ml and is preferably equal to  $0.75 \times 10^6$  cells/ml and, at the harvest time, the density is lower than  $2 \times 10^6$  cells/ml, preferably than  $1 \times 10^6$ .
7. **(Original)** The process as claimed in claim 4, wherein the Cell-Factory™ is a 10-chamber unit.
8. **(Original)** The process as claimed in claim 1, wherein TALL lymphocytes are selected from the group consisting of: TALL-104, TALL-107, TALL-103/2 cell lines, optionally genetically modified.
9. **(Original)** Process according to claim 8 wherein TALL are TALL-104 lymphocytes.
10. **(Currently amended)** The process as claimed in ~~any of claims~~ Claim 1 to 9, wherein the complete culture medium in the cell-factory amplification phase also comprises 10% ~~max~~ maximum human serum, preferably in the range of 4 to 6%, still more preferably of 5%, ~~optionally foetal serum in a concentration of 0 to 10% and interleukin in a concentration of 100 comprised from 80 to 120 IU/ml.~~
11. **(Original)** The process as claimed in claim 10, wherein interleukin-2 is added to the cell culture every 48-90 hrs.

12. **(Original)** The process as claimed in claim 10, wherein the cell growth in the homogeneous system takes place in an antibiotic-free culture medium.

13. **(Currently amended)** A process for the preparation of frozen bags of TALL lymphocytes in an amount of at least  $1 \times 10^9$  cells, characterized in ~~the fact that~~ that it comprises the process according to Claim 1 ~~claims 1—12~~.

14. **(Currently amended)** ~~Process~~ The process as claimed in claim 13, wherein the bag is sealed transversally to the bag filling collet at least in two points to create at least a sampling chamber containing a cell culture volume ranging from 0.1 to 1 ml, physically separated from the culture contained in the bag to perform quality controls.

15. **(Currently amended)** ~~Process~~ A process for the preparation of a therapeutic dose of at least  $1 \times 10^9$  TALL lymphocytes in a homogeneous culture characterized in the fact it comprises the process according to Claim 1 ~~claims 1—12~~.

16. **(Original)** The process as claimed in claim 15, wherein the lymphocytes are TALL-104.

17. **(Currently amended)** TALL lymphocytes obtainable according to the process of Claim 1 ~~claims 1—12~~ wherein said lymphocytes are characterised by a  $CD3^+$  and  $CD8^+$  immunologic markers expression of 98% min, preferably  $\geq 99\%$ , and by the  $CD56^+$  marker expression of 95% at least, preferably  $\geq 97\%$ .

18. **(Original)** TALL lymphocytes according to claim 17 characterised by a biological activity, determined by a cytotoxicity assay on appropriate target cells, equal to at least 70% of the control.

19. **(New)** Process according to claim 6 wherein TALL are TALL-104 lymphocytes.

20. **(New)** The process as claimed in Claim 19, wherein the complete culture medium in the cell-factory amplification phase also comprises 10% maximum human serum, preferably in the range of 4 to 6%, still more preferably of 5%, and interleukin in a concentration comprised from 80 to 120 IU/ml.

21. **(New)** A process for the preparation of frozen bags of TALL lymphocytes in an amount of at least  $1 \times 10^9$  cells, characterized in that it comprises the process according to Claim 19.

**Int. Appl. No. : PCT/EP2003/11024**  
**Int. Filing Date : October 6, 2003**

22. (New) The process as claimed in claim 21, wherein the bag is sealed transversally to the bag filling collet at least in two points to create at least a sampling chamber containing a cell culture volume ranging from 0.1 to 1 ml, physically separated from the culture contained in the bag to perform quality controls.

23. (New) The process for the preparation of a therapeutic dose of at least  $1 \times 10^9$  TALL lymphocytes in a homogeneous culture characterized in the fact it comprises the process according to Claim 20.

24. (New) TALL lymphocytes obtainable according to the process of Claim 20 wherein said lymphocytes are characterised by a  $CD3^+$  and  $CD8^+$  immunologic markers expression of 98% min, preferably  $\geq 99\%$ , and by the  $CD56^+$  marker expression of 95% at least, preferably  $\geq 97\%$ .